A new partnership, of pharma companies and research institutions, has been launched to speed the discovery of new, more effective, drugs for patients with tuberculosis. The TB Drug Accelerator, a ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...